Regenerative Medicine Claim Compliance. The FTC fined $5.1M. Don't be next.
FTC vs. Stem Cell Institute of America set a $5.1 million precedent for false stem cell cure claims. Exosomes, PRP, and stem cell marketing face active enforcement. Treating stem cells as systemic cures classifies them as unapproved biological drugs. Scrutexity audits your regenerative medicine pages before regulators do.
Not legal advice. Not regulatory certification. Claim language review only.
The $5.1M Warning
FTC vs. Stem Cell Institute of America set the precedent.
In 2023, the FTC and the State of Florida obtained a $5.1 million judgment against the Stem Cell Institute of America for false and unsubstantiated claims about stem cell treatments. The defendants claimed stem cells could treat Parkinson's disease, multiple sclerosis, COPD, arthritis, and more — without FDA-reviewed clinical evidence.
That case is not an outlier. The FTC has signaled that regenerative medicine marketing is a priority enforcement area. Every clinic offering stem cell therapy, exosome treatments, or PRP — and marketing those services on a website — is operating on active regulatory ground.
Key regulatory doctrine
“Treating stem cells as systemic cures classifies them as unapproved biological drugs.”
This means your marketing language directly determines whether your stem cell therapy is classified under regulatory review as a medical procedure or an unapproved drug — with enforcement consequences that follow the latter.
$5.1M judgment
The FTC vs. Stem Cell Institute of America case resulted in a multi-million dollar penalty for claims that stem cells could treat serious diseases without clinical evidence.
Unapproved biological drug classification
When stem cells, exosomes, or PRP are marketed to treat, cure, or prevent disease, they are classified as unapproved biological drugs — subject to FDA enforcement.
Ongoing FTC priority
The FTC has explicitly identified regenerative medicine marketing as a priority enforcement area with active investigations and penalties.
AI answer amplification
AI engines repeat your website claims. If your pages say 'stem cells cure arthritis,' that claim now lives in ChatGPT, Perplexity, and Google AI answers — multiplying your regulatory exposure surface.
High-risk claim categories
Five claim categories that trigger enforcement.
Each of these claim types has been the basis for FTC or FDA enforcement actions against regenerative medicine clinics. If any appear on your website, you are operating on active regulatory ground.
"Repair damaged tissue"
"Repair," "regenerate," and "restore" are clinical outcome verbs. Using them to describe stem cell or exosome treatments implies a therapeutic effect that — without FDA-reviewed clinical evidence — classifies the treatment as an unapproved biological drug.
"Reverse aging"
Aging reversal claims for stem cell therapy, exosomes, or PRP are among the highest-risk categories. The FTC has specifically pursued clinics making aging-reversal claims for regenerative procedures. These require extensive clinical evidence that most clinics cannot produce.
"Cure osteoarthritis"
Claiming stem cell therapy or PRP can "cure," "treat," or "reverse" osteoarthritis positions the therapy as a treatment for a specific disease — triggering FDA jurisdiction over your marketing as an unapproved drug claim.
"Regenerate organs"
Organ regeneration claims for stem cell treatments are the most extreme category. The FTC vs. Stem Cell Institute of America case specifically focused on claims that stem cells could regenerate organs like the heart, liver, and kidneys.
"Stem cell therapy for X"
Filling in the blank — "Stem cell therapy for Parkinson's," "for autism," "for spinal cord injury," "for COPD" — makes a specific disease-treatment claim. Each requires FDA-reviewed clinical evidence that hardly any clinic marketing stem cell therapies can provide.
What we review
Six claim categories reviewed on every regenerative medicine page.
Disease-treatment framing
Whether your pages frame stem cell, exosome, or PRP therapy as a treatment, cure, or mitigation for a named disease or condition.
"Regenerative" language
Whether "regenerate," "repair," "rebuild," "restore," or similar terms are used in a way that implies therapeutic outcome without supporting evidence.
Exosome & PRP claims
Specific marketing language around exosome therapy and platelet-rich plasma reviewed for substantiation and disease-treatment framing.
FDA status disclosure
Whether your pages accurately disclose that stem cell therapies are not FDA-approved for systemic disease treatment and are regulated as biological drugs.
Testimonial & outcome framing
Patient stories, before/after language, and anecdotal outcome claims reviewed against FTC substantiation requirements.
AI answer surfaces
How ChatGPT, Perplexity, and Google AI Overviews describe your regenerative medicine services — including whether they repeat unsubstantiated claims.
Pricing
Protect your regenerative medicine practice.
Regenerative Medicine Claim Report
$497 one-time
Full claim inventory of your regenerative medicine pages. Every flagged claim — disease-treatment framing, stem cell language, exosome marketing — gets a risk label, evidence map, and safer rewrite.
Get the $497 AuditClaim Cleanup Record
$1,997 one-time
Done-for-you: safer rewrites executed across your regenerative medicine pages. Final Claim Cleanup Record PDF — a structured record of what changed, why, and what public support now backs each claim.
Book Claim Cleanup RecordOngoing Monitoring
from $1,497/mo per month
Monthly re-scan of your regenerative medicine pages and AI answer surfaces. Get alerted when new risk language appears, when FTC enforcement actions occur, and when AI answers begin referencing your site in new ways.
Start MonitoringQuestions
What regenerative medicine clinics need to know.
Regenerative medicine marketing reviewed. Before the FTC arrives.
Scrutexity does not provide medical, legal, regulatory, clinical, or prescribing advice. It does not certify compliance or guarantee ad approvals, rankings, AI answers, or revenue outcomes. It reviews public-facing claims against visible support and identifies proof gaps, risky language, and safer rewrite options.